| Literature DB >> 27071086 |
Michel Ronjat1, Wei Feng2, Lucie Dardevet3, Yao Dong2, Sawsan Al Khoury3, Franck C Chatelain4, Virginie Vialla5, Samir Chahboun3, Florian Lesage4, Hervé Darbon6, Isaac N Pessah2, Michel De Waard7.
Abstract
The venom peptide maurocalcin (MCa) is atypical among toxins because of its ability to rapidly translocate into cells and potently activate the intracellular calcium channel type 1 ryanodine receptor (RyR1). Therefore, MCa is potentially subjected to posttranslational modifications within recipient cells. Here, we report that MCa Thr(26) belongs to a consensus PKA phosphorylation site and can be phosphorylated by PKA both in vitro and after cell penetration in cellulo. Unexpectedly, phosphorylation converts MCa from positive to negative RyR1 allosteric modulator. Thr(26) phosphorylation leads to charge neutralization of Arg(24), a residue crucial for MCa agonist activity. The functional effect of Thr(26) phosphorylation is partially mimicked by aspartyl mutation. This represents the first case, to our knowledge, of both ex situ posttranslational modification and pharmacological reprogramming of a small natural cystine-rich peptide by target cells. So far, phosphorylated MCa is the first specific negative allosteric modulator of RyR1, to our knowledge, and represents a lead compound for further development of phosphatase-resistant analogs.Entities:
Keywords: maurocalcin; pharmacology; phosphorylation; ryanodine receptor; toxin
Mesh:
Substances:
Year: 2016 PMID: 27071086 PMCID: PMC4855579 DOI: 10.1073/pnas.1517342113
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205